Skip to main
CVAC
CVAC logo

CureVac B.V (CVAC) Stock Forecast & Price Target

CureVac B.V (CVAC) Analyst Ratings

Based on 3 analyst ratings
Hold
Strong Buy 0%
Buy 33%
Hold 67%
Sell 0%
Strong Sell 0%

Bulls say

CureVac NV is strategically positioned within the competitive mRNA sector, leveraging the high value associated with COVID-19 vaccines to expand its portfolio into broader applications. The company demonstrates a strong pipeline with ongoing development programs, which include innovative mRNA vaccines for seasonal influenza, avian influenza, and oncology, indicating robust future revenue potential. As these initiatives progress according to plan, they enhance CureVac's long-term growth prospects and contribute positively to the company's overall financial outlook.

Bears say

CureVac is anticipated to continue incurring net losses at least until it achieves product approval and commercialization, which may extend into the early launch phase. The company faces significant competitive risks against both established products and in-development candidates, which could hinder its market position and future sales potential. Additionally, potential legal and intellectual property risks may further complicate its ability to capitalize on its pipeline, contributing to a challenging financial outlook.

CureVac B.V (CVAC) has been analyzed by 3 analysts, with a consensus rating of Hold. 0% of analysts recommend a Strong Buy, 33% recommend Buy, 67% suggest Holding, 0% advise Selling, and 0% predict a Strong Sell.

This aggregate rating is based on analysts' research of CureVac B.V and is not a guaranteed prediction by Public.com or investment advice.

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About CureVac B.V (CVAC) Forecast

Analysts have given CureVac B.V (CVAC) a Hold based on their latest research and market trends.

According to 3 analysts, CureVac B.V (CVAC) has a Hold consensus rating as of Nov 26, 2025. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $6.83, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $6.83, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

CureVac B.V (CVAC)


Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.